Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Clinical Trial Diversity Efforts Look Beyond COVID-19

Genentech Enlists Trial Sites In Oncology Initiative

Executive Summary

At The Atlantic’s Health Equity Summit, panel discussions highlighted efforts to improve diversity in clinical trials of diseases like lupus, which disproportionately affects women of color.

You may also be interested in...



Novartis Looks To Take Its Diversity Show On The Road

Head of clinical trial diversity and inclusion Kim Fookes spoke with Scrip about Novartis’s US trial diversity initiatives and early plans to expand them abroad.

Breast Cancer Trial Enrollment Illustrates Diversity Challenge

INFOGRAPHIC: Data on industry-sponsored breast cancer studies posted on ClinicalTrials.gov shows how much work remains for drug makers to ensure their studies enroll diverse populations.

Lilly/Verge Pact Shows Resistance To Biopharma AI Is Futile

Deal Snapshot: Following its diabetes deal with Biolojic by four months, Lilly’s partnership with Verge on using AI to discover ALS drugs is just the latest of numerous tech-biopharma tie-ups.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144603

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel